2-苄基-4,6-二氯嘧啶 | 3740-82-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-苄基-4,6-二氯嘧啶
• 英文名称: 2-benzyl-4,6-dichloropyrimidine
• 英文别名: 2-benzyl-4,6-dichloro-pyrimidine；2-Benzyl-4,6-dichlor-pyrimidin
• CAS: 3740-82-7
• 化学式: C₁₁H₈Cl₂N₂
• 分子量: 239.104
• InChiKey: ACEVCJQVGFNGAU-UHFFFAOYSA-N

物化性质

• 熔点：
  56 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 安全说明：
  S26,S37/39

SDS

Name:	2-Benzyl-4 6-dichloropyrimidine 97% Material Safety Data Sheet
Synonym:
CAS:	3740-82-7

Section 1 - Chemical Product MSDS Name:2-Benzyl-4 6-dichloropyrimidine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3740-82-7	2-Benzyl-4,6-dichloropyrimidine	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3740-82-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 56 - 57 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H8Cl2N2
Molecular Weight: 239

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3740-82-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Benzyl-4,6-dichloropyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 3740-82-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3740-82-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3740-82-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苄基-4,6-二氯嘧啶 、 3-氨基丙酸甲酯盐酸盐 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以79%的产率得到3-(2-benzyl-6-chloro-pyrimidin-4-ylamino)-propionic acid methyl ester
  参考文献：
  名称：

  Heterocycle substituted carboxylic acids

  摘要：

  本发明涉及公式（I）的化合物和药用可接受盐，这些化合物在治疗与胰岛素抵抗、瘦素抵抗或高血糖相关的代谢紊乱方面是有用的。本发明的化合物包括蛋白酪氨酸磷酸酶的抑制剂，特别是蛋白酪氨酸磷酸酶-1B（PTP-1B），这些化合物在治疗糖尿病和其他PTP介导的疾病，如癌症、神经退行性疾病等方面是有用的。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述疾病的方法。

  公开号：

  US20060122222A1
• 作为产物：
  描述：

  2-benzyl-1H-pyrimidine-4,6-dione 在 三氯氧磷 作用下， 反应 48.0h， 以70%的产率得到2-苄基-4,6-二氯嘧啶
  参考文献：
  名称：

  2-取代的6-羟基-[3H]-嘧啶-4-酮和4,6-二氯嘧啶的“绿色”合成：改进的策略和机理研究*

  摘要：

  一种改进的路线2-取代的6-羟基- [3 H ^ ] -嘧啶-4-酮4和2-取代的4,6-二氯嘧啶5报道。不使用剧毒反应物，就可以方便地在一锅合成中以1摩尔规模制备化合物4，平均收率可达80％。通常使用少量原料制备的4,6-二氯嘧啶5的平均收率为80％，最多可使用80 g起始原料。4氯化的机理是第一次进行计算研究。结果表明，磷酰氯的氯化反应以交替的磷酸化-氯化方式（途径1）进行，这比以两次磷酸化开始的顺序更可取。本文所述的研究的4，6-二氯嘧啶与二氯磷酸形成强络合物，但与盐酸形成弱络合物（在后处理期间生成）。后面这些配合物解释了在后处理过程中使用碳酸钠水溶液的必要性。为了防止在中间体或最终的二氯嘧啶和未反应的羟基嘧啶之间形成嘧啶鎓盐，可以用强酸（例如二氯磷酸）使后者失活，从而进行氯化反应，但阻止形成盐。

  DOI：

  10.1071/ch14073

文献信息

• MODULATORS FOR AMYLOID BETA
  申请人：Baumann Karlheinz

  公开号：US20090215759A1

  公开（公告）日：2009-08-27

  The invention relates to compounds of formula wherein the substituents are as described in claim 1 . Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式的化合物 其中取代基如权利要求中所述 。式I的化合物是淀粉样蛋白β的调节剂，因此它们可能对治疗或预防与大脑中β-淀粉样蛋白沉积相关的疾病有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病变，遗传性脑出血伴淀粉样变性，荷兰型（HCHWA-D），多梗死性痴呆，拳击性痴呆和唐氏综合征。
• AMINOMETHYL-2-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20080096906A1

  公开（公告）日：2008-04-24

  The present invention relates to compounds of formula I wherein R 1 is selected from the group consisting of hydrogen or lower alkyl; R 2 is hydrogen, lower alkyl, lower alkenyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, —(CH 2 ) x —S-lower alkyl, —(CH 2 ) x —O-lower alkyl, —(CH 2 ) x —NHC(O)O-lower alkyl, —(CH 2 ) x -aryl, and —(CH 2 ) x -heteroaryl; each R 3 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, lower alkyl substituted by halogen, —O—(CH 2 ) m -aryl, —O—(CH 2 ) m -heteroaryl, —(CR 2 ) m -aryl, and —(CR 2 ) m -heteroaryl; each R is selected from the group consisting of hydrogen, lower alkyl and hydroxy; Ar is selected from the group consisting of phenyl, pyrimidin-2-yl, pyrimidin-4-yl and pyridin-3-yl; n is 0, 1 or 2; x is 0, 1, 2 or 3; m is 0 or 1; and to their pharmaceutically active salts.

  本发明涉及以下式I的化合物 其中 R1选择自羟基或较低烷基; R2为氢、较低烷基、较低烯基、被羟基取代的较低烷基、被卤素取代的较低烷基、—(CH2)x—S-较低烷基、—(CH2)x—O-较低烷基、—(CH2)x—NHC(O)O-较低烷基、—(CH2)x-芳基和—(CH2)x-杂环基中的一种; 每个R3选择自氢、较低烷基、较低烷氧基、卤素、羟基、被卤素取代的较低烷基、—O—(CH2)m-芳基、—O—(CH2)m-杂环基、—(CR2)m-芳基和—(CR2)m-杂环基中的一种; 每个R选择自氢、较低烷基和羟基; Ar选择自苯基、嘧啶-2-基、嘧啶-4-基和吡啶-3-基; n为0、1或2; x为0、1、2或3; m为0或1; 以及其药用活性盐。
• PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF
  申请人：Sekiguchi Yoshinori

  公开号：US20090036448A1

  公开（公告）日：2009-02-05

  The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了新型取代嘧啶化合物的公式（I）：这些化合物作为MCH受体拮抗剂。这些化合物在制药组合物中的用途包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症（包括贪食症和厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。
• AMINOMETHYL-4-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20080119535A1

  公开（公告）日：2008-05-22

  The present invention relates to amino-4-methyl imidazoles and pharmaceutically-acceptable salts thereof. The compound may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及氨基-4-甲基咪唑及其药学可接受的盐。该化合物可用于治疗抑郁症、焦虑症、双相障碍、注意力缺陷多动障碍（ADHD）、压力相关障碍、精神病性障碍如精神分裂症、神经系统疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病的治疗。
• Heterocycle Substituted Carboxylic Acids
  申请人：Whitehouse Darren

  公开号：US20080146574A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其在治疗与胰岛素抵抗、瘦素抵抗或高血糖有关的代谢障碍方面具有用途。本发明的化合物包括蛋白酪氨酸磷酸酶的抑制剂，特别是蛋白酪氨酸磷酸酶-1B（PTP-1B），这些抑制剂对于治疗糖尿病和其他PTP介导的疾病，如癌症、神经退行性疾病等，是有用的。本发明还揭示了包括本发明化合物的药物组合物和使用这些化合物治疗上述疾病的方法。